Brief: Dicot Pharma Submits CTA In EU For Phase 2b Study Of LIB-01
17/08/2026 08:29
BRIEF-Dicot Pharma Submits CTA In EU For Phase 2b Study Of LIB-01 Aug 17 (Reuters) - Dicot Pharma AB DICOT.ST:
SUBMITS CTA IN EU FOR PHASE 2B STUDY OF LIB-01
Source text: ID:nMFN4pyZDT
Further company coverage: DICOT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Dicot Pharma AB
See all newsBrief: Dicot Pharma Q2 Net Sales Sek 0.0 Million
Brief: Dicot Pharma Submits CTA In EU For Phase 2b Study Of LIB-01
Brief: Dicot Pharma Recruits Cecilia Driving As CFO
Brief: Dicot Pharma Gets FDA Clearance To Start First Part Of Phase 2B Study With Lib-01 In U.S.
Brief: Dicot Pharma Announces Outcome In Oversubscribed Rights Issue